Jane Wilcox, MD
Advanced Heart Failure and Transplant Cardiology · Chicago, ILNPI 1588820294
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $162,514 of the $220,354 with a category attached, or 73.8%. 15 manufacturers reported payments, led by Boehringer Ingelheim at 49.8% of the total. Reporting peaked in 2022 at $71,593 and has fallen 77.9% since, to $15,805 in 2025. Among advanced heart failure and transplant cardiology clinicians in IL with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 243 payments — averaging $906.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$110K
- Abiomed$56K
- Abbott$24K
- Lilly USA, LLC$21K
- Medtronic$4K
- Amgen$2K
- plus $3K from 9 others
Across 7 payments — averaging $9898.02 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- E.r. Squibb & Sons, L.L.C.$36K
- Astrazeneca UK Limited$20K
- Novartis$7K
- Ionis Pharmaceuticals, Inc.$6K
- Medtronic$200
What the payments were for
- Consulting fees$20,1309%
- Speaking & faculty fees$162,51474%
- Travel & lodging$29,16713%
- Food & beverage$8,5434%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim | 78 | $109,827 |
| Abiomed | 44 | $56,246 |
| Abbott | 79 | $24,440 |
| Lilly USA, LLC | 12 | $20,700 |
| Medtronic(2 entities) | 17 | $4,186 |
| Amgen | 1 | $2,380 |
| Novartis | 3 | $2,010 |
| Boston Scientific | 1 | $150 |
| Edwards Lifesciences | 1 | $120 |
| AstraZeneca | 1 | $103 |
| Cvrx, Inc. | 1 | $74 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 2 | $35 |
| Impulse Dynamics (USA) Inc. | 1 | $31 |
| Briohealth Solutions, Inc. | 1 | $31 |
| Kestra Medical Technology Services, Inc. | 1 | $22 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- JARDIANCE$126,750
- Impella$45,009
- THORATEC HEARTMATE 3 LVAS IMPLANT KIT$9,996
- CARDIOMEMS$9,701
- HeartMate 3 Left Ventricular Assist Device$2,110
- ENTRESTO$1,980
- CardioMEMS HF System$815
- HeartWare HVAD$684
- Arctic Front$510
- InSync$456
- MitraClip$340
- HeartMate 3 Left Ventricular Dev$292
- RELIANCE 4 FRONT$150
- Micra$125
- INSPIRIS RESILIA aortic valve$120
How this compares
$220,354 in reported general payments places this provider in the 90th percentile of 56 advanced heart failure and transplant cardiology providers in Illinois.
See all advanced heart failure and transplant cardiology providers in Illinois →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EntrestoSacubitril/Valsartan | 357 | $460,978 |
| JardianceEmpagliflozin | 203 | $268,634 |
| EliquisApixaban | 96 | $140,901 |
| FarxigaDapagliflozin Propanediol | 70 | $98,286 |
| PrografTacrolimus | 24 | $30,406 |
| Tacrolimus | 115 | $19,361 |
| XareltoRivaroxaban | 12 | $17,386 |
| Repatha SureclickEvolocumab | 17 | $13,585 |
| VeltassaPatiromer Calcium Sorbitex | 13 | $11,949 |
| OzempicSemaglutide | 11 | $10,673 |
| Eplerenone | 70 | $4,254 |
| Metoprolol Succinate | 217 | $4,044 |
| Spironolactone | 219 | $2,411 |
| Bumetanide | 77 | $2,393 |
| Rosuvastatin Calcium | 109 | $2,380 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| NovartisEntresto | $2,010 | $460,978357 claims |
| Boehringer IngelheimJardiance | $109,827 | $268,634203 claims |
| AstraZenecaFarxiga | $103 | $98,28670 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 56 advanced heart failure and transplant cardiology providers in Illinois.
Other advanced heart failure and transplant cardiology in Chicago
- Jonathan RichChicago$327K
- Esther VorovichChicago$224K
- Manreet KanwarChicago$162K
- Jonathan GrinsteinChicago$128K
- Bow ChungChicago$86K
- Quentin YoumansChicago$75K
- Anjan TibrewalaChicago$58K
- Faraz AhmadChicago$36K
- Ike OkwuosaChicago$30K
- Leo GozdeckiChicago$29K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.